14-day Premium Trial Subscription Try For FreeTry Free

Range Low Price High Price Comment
30 days $5.34 $19.02 Monday, 6th May 2024 VKTX stock ended at $78.21. This is 1.61% more than the trading day before Friday, 3rd May 2024. During the day the stock fluctuated 8.40% from a day low at $73.69 to a day high of $79.88.
90 days $17.30 $19.02
52 weeks $16.32 $20.85

Historical Viking Therapeutics prices

Date Open High Low Close Volume
May 06, 2024 $76.97 $79.88 $73.69 $78.21 3 062 858
May 03, 2024 $74.70 $77.68 $72.88 $76.97 3 699 472
May 02, 2024 $78.13 $78.13 $73.41 $75.76 2 008 623
May 01, 2024 $78.31 $80.38 $75.67 $76.43 4 019 180
Apr 30, 2024 $75.00 $80.25 $74.80 $79.58 3 721 079
Apr 29, 2024 $74.54 $76.44 $73.50 $75.42 2 819 048
Apr 26, 2024 $69.00 $74.64 $68.22 $74.31 3 479 935
Apr 25, 2024 $63.00 $69.17 $62.56 $68.86 3 475 165
Apr 24, 2024 $65.75 $67.78 $64.43 $65.07 2 508 976
Apr 23, 2024 $64.55 $67.58 $63.51 $64.93 2 007 609
Apr 22, 2024 $64.13 $64.94 $62.30 $63.85 1 559 887
Apr 19, 2024 $64.54 $65.75 $61.64 $63.42 3 042 497
Apr 18, 2024 $66.13 $66.24 $64.50 $64.67 2 380 846
Apr 17, 2024 $69.00 $69.78 $66.21 $66.47 1 967 128
Apr 16, 2024 $66.27 $68.48 $65.50 $67.95 2 070 565
Apr 15, 2024 $68.51 $70.00 $66.25 $66.95 2 116 732
Apr 12, 2024 $70.00 $70.81 $68.43 $68.62 2 723 137
Apr 11, 2024 $70.94 $71.73 $70.39 $70.87 1 698 895
Apr 10, 2024 $70.50 $71.78 $68.37 $71.65 3 088 085
Apr 09, 2024 $75.22 $76.18 $71.75 $72.83 2 570 393
Apr 08, 2024 $75.43 $76.81 $74.03 $75.88 2 254 030
Apr 05, 2024 $73.69 $77.77 $72.41 $76.45 2 716 576
Apr 04, 2024 $79.05 $80.10 $73.33 $73.68 3 352 885
Apr 03, 2024 $77.00 $80.74 $76.08 $78.44 2 284 341
Apr 02, 2024 $77.00 $78.45 $73.40 $77.35 3 977 760
Click to get the best stock tips daily for free!

About Viking Therapeutics

Viking Therapeutics Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also dev... VKTX Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT